본문 바로가기

US · 21 CFR

21 CFR Part 601

Licensing

eCFR, up to date as of 2026-11-12

조항 목차

  1. 601.2Applications for biologics licenses; procedures for filing.
  2. 601.3Complete response letter to the applicant.
  3. 601.4Issuance and denial of license.
  4. 601.5Revocation of license.
  5. 601.6Suspension of license.
  6. 601.7Procedure for hearings.
  7. 601.8Publication of revocation.
  8. 601.9Licenses; reissuance.
  9. 601.12Changes to an approved application.
  10. 601.14Regulatory submissions in electronic format.
  11. 601.15Foreign establishments and products: samples for each importation.
  12. 601.20Biologics licenses; issuance and conditions.
  13. 601.21Products under development.
  14. 601.22Products in short supply; initial manufacturing at other than licensed location.
  15. 601.27Pediatric studies.
  16. 601.28Annual reports of postmarketing pediatric studies.
  17. 601.29Guidance documents.
  18. 601.30Scope.
  19. 601.31Definition.
  20. 601.32General factors relevant to safety and effectiveness.
  21. 601.33Indications.
  22. 601.34Evaluation of effectiveness.
  23. 601.35Evaluation of safety.
  24. 601.40Scope.
  25. 601.41Approval based on a surrogate endpoint or on an effect on a clinical endpoint other than survival or irreversible morbidity.
  26. 601.42Approval with restrictions to assure safe use.
  27. 601.43Withdrawal procedures.
  28. 601.44Postmarketing safety reporting.
  29. 601.45Promotional materials.
  30. 601.46Termination of requirements.
  31. 601.50Confidentiality of data and information in an investigational new drug notice for a biological product.
  32. 601.51Confidentiality of data and information in applications for biologics licenses.
  33. 601.70Annual progress reports of postmarketing studies.
  34. 601.90Scope.
  35. 601.91Approval based on evidence of effectiveness from studies in animals.
  36. 601.92Withdrawal procedures.
  37. 601.93Postmarketing safety reporting.
  38. 601.94Promotional materials.
  39. 601.95Termination of requirements.
표지·목차 원문

Authority:15 U.S.C. 1451-1561; 21 U.S.C. 321, 351, 352, 353, 355, 356b, 360, 360c-360f, 360h-360j, 371, 374, 379e, 381; 42 U.S.C. 216, 241, 262, 263, 264; sec 122, Pub. L. 105-115, 111 Stat. 2322 (21 U.S.C. 355 note), sec 7002(e), Pub. L. 111-148, 124 Stat. 817, as amended by sec. 607, Division N, Pub. L. 116-94, 133 Stat. 3127.

Source:38 FR 32052, Nov. 20, 1973, unless otherwise noted.

출처: U.S. Office of the Federal Register / GPO — eCFR · U.S. federal government work — public domain (17 U.S.C. §105). eCFR is an editorial compilation, not an official legal edition of the CFR. · 수집일 2026-11-16

Weekly Newsletter

FDA·EU·식약처 실사 지적, 매주 받아 보세요

FDA·EMA·식약처의 새 지적과 조치를 공식 원문 링크와 함께 보내드립니다. 사이트에 새로운 기능이 생기면 함께 안내드립니다. 구독은 언제든 한 번의 클릭으로 해지할 수 있습니다.

이번 주 소식 먼저 보기

확인 메일의 버튼을 누르면 구독이 완료됩니다 · 언제든 해지할 수 있습니다